Pulmovant
Roivant Sciences subsidiary developing an inhaled sGC activator in-licensed from Bayer
Subsidiary of Roivant Sciences Ltd. (ROIV) · United States
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Soluble guanylate cyclaseSmall molecule | Pulmonary Hypertension Associated with Interstitial Lung Disease |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2029 (1)
January 2029 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.